Therefore, in this study, the synergistic effects of STING and TLR9 agonists and the immunological mechanisms underlying tumor regression and CAFs’ infiltration of the TME were studied in a preclinical colorectal tumor model. The gene discussed is TLR9; the disease is neoplasm.